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Ⅰ．Introduction
 In 1987, Chamot et al［1］reported a syndrome 
characterized by acne, pustulosis, hyperostosis, and 
osteitis, which he termed “le syndrome acne pustulose 
hyperostose osteite” and abbreviated as “SAPHO.” 
Thereafter, Benhamou et al［2］included synovitis to 
the syndrome and renamed it as SAPHO syndrome 
using the initial of synovitis instead of syndrome. Table 
1 shows the diagnostic criteria for this syndrome［3］. 
The patients with SAPHO syndrome frequently visit 
orthopedic clinic first because of their bone and joint 
involvement. Here we describe the case of a patient with 
SAPHO syndrome successfully treated with alendronate.
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SUMMARY
Syndrome acne pustulose hyperostose osteite （SAPHO） is characterized by synovitis, acne, 
pustulosis, hyperostosis, and osteitis. Here we report the case of a patient with SAPHO syndrome 
successfully treated with alendronate. A 34-year-old man presented with a one-year history of recurrent 
pain at the ulnar side of the right forearm. A roentgenogram and a CT scan revealed the hyperostotic 
consolidation of the ulna with radiolucent area. Bone scintigram displayed increased uptake at the 
diaphysis of the ulna, sterno-clavicular joints, and iliosacral joints. Based on these findings, bone 
curettage was performed. The surgically resected specimen revealed chronic recurrent osteomyelitis, 
suggesting SAPHO syndrome. We administrated 35 mg of alendronate per week orally. The ulnar pain 
disappeared for three weeks after this administration. The treatment continued for 13 months, and 
the patient remained completely pain-free 12 months after the cessation of alendronate. Furthermore, 
bone scintigrams gradually improved. Alendronate possibly brought initial pain relief through its anti-
inflammatory effect and long-term pain relief by suppressing bone remodeling.
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Ⅱ．Case
 A 34-year-old man presented with a one-year 
history of recurrent pain at the ulnar side of the right 
forearm. He also had dermatosis for 10 years （Fig. 1）. 
The patient’s family history was not remarkable. The 
roentgenogram showed periosteal reaction （Fig. 2a, 
b） and the CT scan showed hyperostotic consolidation 
of the ulna with radiolucent area （Fig. 2c, and d）. 
The ulnar lesion was initially suspected to be a bone 
tumor; however, biopsied specimen suggested chronic 
osteomyelitis of the right ulna. Consequently, the patient 
was referred to our hospital for surgical treatment. 
A bone scintigram displayed an increased uptake in 
the diaphysis of the ulna, sterno-clavicular joints, and 
iliosacral joints （Fig. 3a and b）. Blood chemistry 
showed no abnormalities, including erythrocyte 
sedimentation rate （ESR）, C-reactive protein, and 
HLA-B27. As a result, we performed bone curettage. 
The surgically resected specimen revealed a chronic 
recurrent osteomyelitis, suggesting SAPHO syndrome. 
Bacterial culture assessment also showed negative 
Fig. 1　 Dermatosis with acne shown by the patient in his 
first visit to our clinic Fig. 3　a, b. Bone scintigram at initial examination
Fig. 2　 a, b. The roentgenograms of the right forearm 
showing hyperostosis with periosteal reaction in 
the diaphysis （arrows）
c, d. The axial and longitundinal reconstructive CT 
images of the right ulna
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Table 1　 Diagnostic Criteria for Synovitis, Acne, Pustulosis, 
Hyperostosis, and Osteitis （SAPHO） Syndrome
［3］
Inclusion Criteria
1. The skin manifestations of severe acne
2. The skin manifestation of palmoplantar pustulosis
3. Hyperostosis with or without dermatosis
4. Chronic recurrent multifocal osteomyelitis involving the 
axial or peripheral skeleton with or without dermatosis
Exclusion Criteria
1. Septic Osteomyelitis
2. Infectious chest wall arthritis
3. Infectious palmoplantar pustulosis
4. Palmoplantar keratodermia
5. Diffuse idiopathic skeletal hyperostosis
6. The osteoarticular manifectations of retinoid therapy
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results, and finally the lesions observed were attributed 
to SAPHO syndrome. The patient remained symptom-
free for two years after surgery; however, the ulnar pain 
gradually recurred during the next one-year period. 
The patient used non-steroidal anti-inflammatory drugs 
（NSAIDs） to manage intractable ulnar pain. No other 
medical treatment was effective, including antibiotics 
（minocycline 200 mg or cefotiam 600 mg） or vitamin 
H. We finally administrated 35 mg of alendronate per 
week orally, which has been proven effective to reduce 
the pain. After 3 weeks of treatment, the ulnar pain 
gradually disappeared. This treatment was continued for 
13 months, and 12 months after ending the treatment, 
the patient continued to report no pain. The periosteal 
reaction disappeared （Fig. 4a, b）. The CT scan 
revealed moderate hyperostosis with enlargement of the 
intramedullary canal （Fig. 4c）. Bone scintigrams also 
showed gradual improvement （Fig. 5a, b, and c）. 
Ⅲ． Discussion
 Spondyloarthropathy is relatively rare in Japan. Its 
incidence is reportedly 0.00144 per 100×103 habitants, 
which is approximately 1/10 to 1/200 of the incidences 
reported in western countries［4］. Accurate incidence 
figures from Japan remain unknown; however, SAPHO 
is likely to be rarer than spondyloarthropathy. Half of 
the patients presenting SAPHO syndrome also show 
palmoplantar pustulosis. Hyperostosis and synovitis 
are also frequently reported at the sterno-clavicular 
joints, spine, and/or iliosacral joints. SAPHO syndrome 
sometimes affect long bones of the lower and upper 
limbs［5,6］. 
 Moreover, the blood chemistry parameters frequently 
show a slight increase in the inflammatory response 
without any specific findings. Positive HLA-B27 is 
reported in 13％ of patients with SAPHO syndrome
［6］; however, the case described here was negative for 
HLA-B27. In this case, diagnostic imaging, including 
roentgenogram, CT, and MRI, revealed hyperostotic 
changes. Bone scintigrams are also useful in this type 
of diagnosis for providing a whole-body evaluation. In 
addition, 18FDG-PET has been reported to be useful 
to identify active SAPHO syndrome［7］. In the case 
reported here, a bone scintigram revealed an ulnar lesion 
and an asymptomatic lesion of the sterno-clavicular and 
the sacroiliac joints. We often recommend this type of 
 
a                   b c
Fig. 4　a, b. Roentgenograms at final follow up
c. Reconstructive CT image at final follow 
up
Fig. 5　a. Bone scintigram before alendronate treatment
b. Bone scintigram one month before the cessation 
of the treatment
c. Bone scintigram one year after the cessation of 
the treatment
a                  b              c
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assessment when SAPHO syndrome that is characterized 
by the involvement of multiple musculoskeletal joints is 
suspected. 
 Two hypotheses have been proposed to explain 
the pathogenesis of the SAPHO syndrome. The first 
hypothesis involves blood-borne low virulence bacterial 
or viral pathogens triggering an autoimmune response 
in the lesion. The second hypothesis suggests a relation 
with sero-negative spondylo-arthropathies［3］. In the 
present case, the patient did not show any associated 
general disease or apparent spondyloarthropathies, 
except for an asymptomatic sacroiliac joint lesion. 
 The etiology of the SAPHO syndrome is largely 
unknown; consequently, the treatment tends to be 
mainly symptomatic. Current treatment options include 
NSAIDs, colchicine, corticosteroids, and/or disease-
modifying agents such as methotrexate, sulfasalazine, 
or infliximab. Other treatments reported included trials 
involving antimicrobial agents and local corticosteroid 
injections［8］. 
 Some authors reported the effectiveness of 
bisphosphonate to treat SAPHO syndrome［9,10］
［11］. Our patient was treated with alendronate for 13 
months, and although further follow-up checks are 
recommended, the patient has been symptom-free for 
one year following the end of the alendronate treatment. 
Bisphosphonate is an anti-osteoclastic agent used for 
the treatment of osteoporosis. Furthermore, it has been 
reported to have anti-inflammatory effects. In addition, 
Kerrison et al. showed that the anti-inflammatory effect 
shown by bisphosphonate can effectively suppress the 
production of interleukin 1, interleukin 6, and TNF-α
［12］. They also stated that an acute phase response is 
usually only observed following the first intravenous 
administration of pamidronate and is rarely subsequently 
observed［12］. This type of anti-inflammatory effect 
could explain the initial pain relief effect shown by 
alendronate, whereas the subsequent long-term pain 
relieved achieved by this treatment could relate to the 
suppression of bone remodeling.
 Thus, any anti-inflammatory agents are likely to 
be effective to treat the symptoms associated with the 
SAPHO syndrome; however, bisphosphonate may be 
unique in its ability to achieve long-time pain relief even 
after the end of the treatment.
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